Jane E. Kiernan - 20 May 2025 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Director
Issuer ticker: TMCI
Reported as of: 20 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2025, 17:30:09 UTC
Prior SEC filing: 15 Nov 2024
Next SEC filing: 19 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Jane E. Kiernan

Key filing fact

Jane E. Kiernan filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 21 May 2025.

Key facts

This page summarizes Jane E. Kiernan's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 May 2025, 17:30.

Change

Previous filing in this sequence was filed on 15 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001379171 Primary reporting owner

Kiernan Jane E

Relationship: Director
Address: C/O TREACE MEDICAL CONCEPTS, INC., 100 PALMETTO PARK PLACE, PONTE VEDRA
Signature: /s/ Lisa Taylor as Attorney-in-fact for Jane E. Kiernan
Signature date: 21 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Award

Transaction value: $0
Shares: +23,917
Change %: +60%
Price: $0.000000
Shares after: 63,949
Date: 20 May 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 20, 2026 or (b) the date of the 2026 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the Issuer's Common Stock issuable upon settlement of the RSUs until the earlier of a change in control or the Reporting Person's separation of service to the Issuer.

Footnote F2

Includes 24,861 restricted stock units.